Undersøgelse for at evaluere sikkerheden og effektiviteten af Lenacapavir (GS-6207) i kombination med et optimeret baggrundsregime (OBR) i tunge behandlingserfarne deltagere, der lever med HIV-1-infektion med multidrug-resistens (CAPELLA)
Et fase 2/3-studie for at evaluere sikkerheden og effektiviteten af langtidsvirkende capsidhæmmer GS-6207 i kombination med en optimeret baggrundsbehandling i kraftig behandling Erfarne mennesker, der lever med HIV-1-infektion med multiresistens
The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen for 14 days (functional monotherapy) in people with human immunodeficiency virus type 1 (HIV-1) (PWH) with multi-drug resistance (MDR).
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Ottawa, Canada, K1H 8L6
- The Ottawa Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 2C9
- Vancouver ID Research and Care Centre Society
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1K2
- Maple Leaf Research/Maple Leaf Medical Clinic
-
-
Quebec
-
Montreal, Quebec, Canada, H2L 4E9
- Clinique de médecine urbaine du Quartier Latin
-
-
-
-
-
Santo Domingo, Dominikanske republik, 10103
- Instituto Dominicano de Estudios Virologicos (IDEV)
-
Santo Domingo, Dominikanske republik, 10514
- Hospital Dr. Salvador Bienvenido Gautier
-
-
-
-
California
-
Los Angeles, California, Forenede Stater, 90036
- Ruane Clinical Research Group Inc
-
Los Angeles, California, Forenede Stater, 90069
- Mills Clinical Research
-
Palm Springs, California, Forenede Stater, 92264
- Eisenhower Health Center at Rimrock
-
Sacramento, California, Forenede Stater, 95817
- One Community Health
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06510
- Yale University; School of Medicine
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20017
- Washington Health Institute
-
-
Florida
-
DeLand, Florida, Forenede Stater, 32720
- Midland Florida Clinical Research Center, LLC
-
Fort Lauderdale, Florida, Forenede Stater, 33316
- Gary J. Richmond, M.D., P.A.
-
Ft. Pierce, Florida, Forenede Stater, 34982
- Midway Immunology and Research Center
-
Hialeah, Florida, Forenede Stater, 33016
- Floridian Clinical Research
-
Miami Beach, Florida, Forenede Stater, 33139
- AIDS Healthcare Foundation - South Beach
-
Orlando, Florida, Forenede Stater, 32803
- Orlando Immunology Center
-
Tampa, Florida, Forenede Stater, 33614
- St. Joseph's Hospital Comprehensive Research Institute
-
West Palm Beach, Florida, Forenede Stater, 33401
- Triple O Research Institute, P.A.
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30309
- Atlanta ID Group, PC
-
Atlanta, Georgia, Forenede Stater, 30308
- Emory Hospital Midtown Infectious Disease Clinic
-
Savannah, Georgia, Forenede Stater, 31401
- Chatham County Health Department
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60613
- Howard Brown Health Center
-
Chicago, Illinois, Forenede Stater, 60657
- Northstar Healthcare
-
-
Michigan
-
Berkley, Michigan, Forenede Stater, 48072
- Be Well Medical Center
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63139
- Southampton Healthcare, Inc.
-
-
New York
-
Flushing, New York, Forenede Stater, 11355
- New York-Presbyterian/Queens
-
Manhasset, New York, Forenede Stater, 11030
- North Shore University Hospital/Division of Infectious Diseases
-
The Bronx, New York, Forenede Stater, 10461
- Jacobi Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28209
- Atrium Health- Infectious Disease Consultants
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02906
- The Miriam Hospital
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38163
- 1265 Union Avenue, 8 East
-
-
Texas
-
Austin, Texas, Forenede Stater, 78705
- Central Texas Clinical Research
-
Bellaire, Texas, Forenede Stater, 77401
- St Hope Foundation
-
Dallas, Texas, Forenede Stater, 75246
- North Texas Infectious Diseases Consultants, P.A.
-
Dallas, Texas, Forenede Stater, 75215
- AIDS Arms, Inc. DBA Prism Health North Texas
-
Houston, Texas, Forenede Stater, 77098
- The Crofoot Research Center, INC.
-
Longview, Texas, Forenede Stater, 75605
- DCOL Center for Clinical Research
-
-
Virginia
-
Annandale, Virginia, Forenede Stater, 22003
- Clinical Alliance for Research and Education - Infectious Diseases, LLC (CARE-ID)
-
-
-
-
-
Marseille, Frankrig, 13009
- Hôpital Sainte-Marguerite
-
Paris, Frankrig, 75012
- Hôpital Saint-Antoine
-
Paris, Frankrig, 75018
- Hôpital Bichat-Claude Bernard
-
Paris, Frankrig, 75010
- Hôpital Saint-Louis
-
-
-
-
-
Bergamo, Italien, 24127
- University of Naples Federico II
-
Brescia, Italien, 25100
- UOC Malattie Infettive - ASST Spedali Civili Di Brescia - Piazzale Spedali Civili 1
-
Milan, Italien, 20127
- Divisione di Malattie Infettive, IRCCS Ospedale San Raffaele
-
Roma, Italien, 00149
- U.O.C. IMMUNODEFICIENZE VIRALI - Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS
-
Rome, Italien, 00168
- U.O.C. Malattie Infettive - Fondazione Policlinico Universitario A. Gemelli IRCCS
-
-
-
-
-
Nagoya, Japan, 460-0001
- National Hospital Organization Nagoya Medical Center
-
Osaka, Japan, 540-0006
- National Hospital Organization Osaka National Hospital
-
Tokyo, Japan, 1600023
- Tokyo Medical University Hospital
-
Tokyo, Japan, 1628655
- Center Hospital of the National Center for Global Health and Medicine
-
-
-
-
-
Badalona, Spanien, 08916
- Hospital Universitari Germans Trías i Pujol
-
Barcelona, Spanien, 08036
- Hospital Clinic de Barcelona
-
Madrid, Spanien, 28046
- Hospital Universitario La Paz
-
Seville, Spanien, 41013
- Hospital Universitario Virgen del Rocío
-
-
-
-
-
Durban, Sydafrika, 4302
- Durban International Clinical Research Site, Enhancing Care Foundation
-
Johannesburg, Sydafrika, 2092
- Helen Joseph Hospital
-
Pretoria, Sydafrika, 87
- Vx Pharma
-
Soweto, Sydafrika, 2013
- Perinatal HIV Research Unit (PHRU)
-
-
-
-
-
Kaohsiung City, Taiwan, 81362
- Kaohsiung Veterans General Hospital
-
Kaohsiung City, Taiwan, 80756
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
New Taipei City, Taiwan, 22060
- Far Eastern Memorial Hospital
-
Taipei, Taiwan, 10048
- National Taiwan University Hospital
-
Taoyuan City, Taiwan, 33004
- Taoyuan General Hospital, Ministry of Health and Welfare
-
-
-
-
-
Bangkok, Thailand, 10700
- Faculty of Medicine Siriraj Hospital, Mahidol University
-
Bangkok, Thailand, 10400
- Faculty of Medicine Ramathibodi Hospital, Mahidol University
-
Bangkok, Thailand, 10330
- Thai Red Cross AIDS Research Center
-
Khon Kaen, Thailand, 40002
- Faculty of Medicine, Khon Kaen University
-
Nonthaburi, Thailand, 11000
- Bamrasnaradura Infectious Diseases Institute
-
-
-
-
-
Essen, Tyskland, 45122
- Universitätsklinikum Essen, Klinik für Dermatologie und Venerologie
-
Hamburg, Tyskland, 20146
- ICH Study Center GmbH & Co. KG
-
-
Hesse
-
Frankfurt am Main, Hesse, Tyskland, 60590
- Universitätsklinikum Frankfurt, Medizinische Klinik II
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Adult aged ≥ 18 years (at all sites) or adolescent aged ≥ 12 and weighing ≥ 35 kg (at sites in North America and Dominican Republic)
- Currently receiving a stable failing ARV regimen for > 8 weeks
- Have HIV-1 RNA ≥ 400 copies/mL at screening
- Have multidrug resistance (resistance to ≥2 agents from ≥3 of the 4 main classes of ARV)
- Have no more than 2 fully active ARV remaining from the 4 main classes that can be effectively combined to form a viable regimen
- Able and willing to receive an OBR together with lenacapavir
- No Hepatitis C virus (HCV) ongoing infection
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Cohort 1A: Lenacapavir
Participants with HIV-1 ribonucleic acid (RNA) ≥ 400 copies/mL and with a <0.5 log10 HIV-1 RNA decline at Cohort Selection visit compared with screening visit will receive oral lenacapavir (LEN) 600 mg tablet on Days 1 and 2 and 300 mg tablet on Day 8, while continuing their failing regimen in the blinded Functional Monotherapy Period (Baseline to Day 14); followed by unblinded Maintenance Period where participants will receive subcutaneous (SC) LEN 927 mg and will initiate an optimized background regimen (OBR) at Day 1 SC Visit (14 days after the first dose of oral LEN). At Week 52 (relative to Day 1 SC), participants will be given an option to receive SC lenacapavir injections every 6 months (26 weeks), while continuing their OBR, until the product becomes accessible to participants through an access program or until Gilead elects to discontinue the study in the country. |
Tablets administered without regard to food
Andre navne:
Administered in the abdomen via subcutaneous injections
Andre navne:
Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen. Optimized background regimen as prescribed by the Investigator |
|
Placebo komparator: Cohort 1B: Placebo to Lenacapavir
Participants with HIV-1 RNA ≥ 400 copies/mL and with a <0.5 log10 HIV-1 RNA decline at the Cohort Selection visit compared with screening visit will receive oral LEN placebo on Days 1, 2, and 8 while continuing their failing regimen in the blinded Functional Monotherapy Period (Baseline to Day 14); followed by unblinded Maintenance Period where participants will receive oral LEN 600 mg on Days 15 and 16 and 300 mg on Day 22, and will initiate an OBR on Day 15. At Day 1 SC (14 days after the first dose of oral LEN), participants will receive SC LEN 927 mg while continuing OBR. At Week 52 (relative to Day 1 SC), participants will be given an option to receive SC lenacapavir injections every 6 months (26 weeks), while continuing their OBR, until the product becomes accessible to participants through an access program or until Gilead elects to discontinue the study in the country. |
Tablets administered without regard to food
Andre navne:
Administered in the abdomen via subcutaneous injections
Andre navne:
Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen. Optimized background regimen as prescribed by the Investigator Tablets administered without regard to food |
|
Eksperimentel: Cohort 2: Lenacapavir
Participants with a ≥ 0.5 log10 copies/mL HIV-1 RNA decline at the Cohort Selection Visit compared with the screening visit or with HIV-1 RNA < 400 copies/mL or if Cohort 1 is fully enrolled will receive oral LEN 600 mg tablet on Days 1 and 2 and 300 mg tablet on Day 8, and will initiate an OBR on Day 1 in Oral Lead-in Period (Baseline to Day 14); followed by Maintenance Period where participants will receive SC LEN 927 mg at Day 1 SC Visit (14 days after the first dose of oral LEN) while continuing their OBR. At Week 52 (relative to Day 1 SC), participants will be given an option to receive SC lenacapavir injections every 6 months (26 weeks), while continuing their OBR, until the product becomes accessible to participants through an access program or until Gilead elects to discontinue the study in the country. |
Tablets administered without regard to food
Andre navne:
Administered in the abdomen via subcutaneous injections
Andre navne:
Optimized background regimen as prescribed by the Investigator |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Procentdel af deltagere i kohorte 1, der opnår en reduktion på ≥ 0,5 log10 kopier/ml i human immundefektvirus-1 ribonukleinsyre (HIV-1 RNA) fra baseline til slutningen af den funktionelle monoterapiperiode
Tidsramme: Baseline op til dag 1 SC-besøg (14 dage efter den første dosis oral lencapavir) eller dag 15
|
Baseline op til dag 1 SC-besøg (14 dage efter den første dosis oral lencapavir) eller dag 15
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants in Cohort 1 With Plasma HIV-1 RNA < 50 Copies/mL at Week 26 Based on the US FDA-defined Snapshot Algorithm
Tidsramme: Week 26 (26 weeks after first dose of subcutaneous lenacapavir)
|
The percentage of participants in cohort 1 with plasma HIV-1 RNA < 50 copies/mL at Week 26 was analyzed using the United States Food and Drug Administration (US FDA)-defined snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. |
Week 26 (26 weeks after first dose of subcutaneous lenacapavir)
|
|
Percentage of Participants in Cohort 1 With Plasma HIV-1 RNA < 200 Copies/mL at Week 26 Based on the US FDA-defined Snapshot Algorithm
Tidsramme: Week 26 (26 weeks after first dose of subcutaneous lenacapavir)
|
The percentage of participants in cohort 1 with plasma HIV-1 RNA < 200 copies/mL at Week 26 was analyzed using the US FDA-defined snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. |
Week 26 (26 weeks after first dose of subcutaneous lenacapavir)
|
|
Percentage of Participants in Cohort 1 With Plasma HIV-1 RNA < 50 Copies/mL at Week 52 Based on the US FDA-defined Snapshot Algorithm
Tidsramme: Week 52 (52 weeks after first dose of subcutaneous lenacapavir)
|
The percentage of participants in cohort 1 with plasma HIV-1 RNA < 50 copies/mL at Week 52 was analyzed using the US FDA-defined snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Percentages were rounded off. |
Week 52 (52 weeks after first dose of subcutaneous lenacapavir)
|
|
Percentage of Participants in Cohort 1 With Plasma HIV-1 RNA < 200 Copies/mL at Week 52 Based on the US FDA-defined Snapshot Algorithm
Tidsramme: Week 52 (52 weeks after first dose of subcutaneous lenacapavir)
|
The percentage of participants in cohort 1 with plasma HIV-1 RNA < 200 copies/mL at Week 52 was analyzed using the US FDA-defined snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Percentages were rounded off. |
Week 52 (52 weeks after first dose of subcutaneous lenacapavir)
|
|
Percentage of Participants in Combined Cohorts 1 and 2 With Plasma HIV-1 RNA < 50 Copies/mL at Week 104 Based on the US FDA-defined Snapshot Algorithm
Tidsramme: Week 104 (104 weeks after first dose of subcutaneous lenacapavir)
|
The percentage of participants in combined cohorts 1 and 2 with plasma HIV-1 RNA < 50 copies/mL at Week 104 was analyzed using the US FDA-defined snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Percentages were rounded off. |
Week 104 (104 weeks after first dose of subcutaneous lenacapavir)
|
|
Percentage of Participants in Combined Cohorts 1 and 2 With Plasma HIV-1 RNA < 200 Copies/mL at Week 104 Based on the US FDA-defined Snapshot Algorithm
Tidsramme: Week 104 (104 weeks after first dose of subcutaneous lenacapavir)
|
The percentage of participants in combined cohorts 1 and 2 with plasma HIV-1 RNA < 200 copies/mL at Week 104 was analyzed using the US FDA-defined snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Percentages were rounded off. |
Week 104 (104 weeks after first dose of subcutaneous lenacapavir)
|
|
Percentage of Participants in Combined Cohorts 1 and 2 With Plasma HIV-1 RNA < 50 Copies/mL at Week 156 Based on the US FDA-defined Snapshot Algorithm
Tidsramme: Week 156 (156 weeks after first dose of subcutaneous lenacapavir)
|
The percentage of participants in combined cohorts 1 and 2 with plasma HIV-1 RNA < 50 copies/mL at Week 156 was analyzed using the US FDA-defined snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Percentages were rounded off. |
Week 156 (156 weeks after first dose of subcutaneous lenacapavir)
|
|
Percentage of Participants in Combined Cohorts 1 and 2 With Plasma HIV-1 RNA < 200 Copies/mL at Week 156 Based on the US FDA-defined Snapshot Algorithm
Tidsramme: Week 156 (156 weeks after first dose of subcutaneous lenacapavir)
|
The percentage of participants in combined cohorts 1 and 2 with plasma HIV-1 RNA < 200 copies/mL at Week 156 was analyzed using the US FDA-defined snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Percentages were rounded off. |
Week 156 (156 weeks after first dose of subcutaneous lenacapavir)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Gilead Study Director, Gilead Sciences
Publikationer og nyttige links
Generelle publikationer
- Segal-Maurer S, Castagna A, Berhe M, et al. Potent Antiviral Activity of Lenacapavir in Phase 2/3 in Heavily ART-Experienced PWH [Abstract 127]. Presented at: Conference on Retroviruses and Opportunistic Infections; 2021 March 6-10.
- Ogbuagu O, Ratanasuwan W, Avihingsanon A, Chetchotisakd P, Wiznia A, Kimberly W, et al. Lenacapavir Efficacy in CAPELLA Patients with No Fully Active Agents in Optimized Background Regimen. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI), 2024 March 3-6
- Margot N, Pennetzdorfer N, Naik V, Rhee M, Callebaut C. Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA. Antivir Ther. 2023 Dec;28(6):13596535231220754. doi: 10.1177/13596535231220754.
- Castagna A, Blanco Arevalo JL, Molina JM, Antinori A, Castelli F, Yazdanpanah Y, et al. Follow-Up of Injection Site Reactions in Clinical Studies of People Using Lenacapavir Every 6 Months for HIV Treatment [Poster eP.A.104]. Presented at: European AIDS Conference (EACS), 2023 October 18-21
- Margot N, Jogiraju V, VanderVeen L, Naik V, Dvory-Sobol H, Rhee MS, et al. Resistance Analysis of Long-Acting Lenacapavir in Heavily Treatment-Experienced People with HIV after 104 Weeks of Treatment [PS8 O4]. Presented at: European AIDS Conference (EACS), 2023 18-21 October
- Ogbuagu O, DeJesus E, Berhe M, Richmond GJ, Ruane PJ, Sinclair GI, et al. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results [Poster 1596]. Presented at: IDWeek, 2023 11-15 October
- Ogbuagu O, Segal-Maurer S, Ratanasuwan W, Avihingsanon A, Brinson C, Workowski K, Antinori A, Yazdanpanah Y, Trottier B, Wang H, Margot N, Dvory-Sobol H, Rhee MS, Baeten JM, Molina JM; GS-US-200-4625 investigators. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial. Lancet HIV. 2023 Aug;10(8):e497-e505. doi: 10.1016/S2352-3018(23)00113-3. Epub 2023 Jul 11.
- Ogbuagu O, Avihingsanon A, Segal-Maurer S, Wang H, Rhee MS, Dvory-Sobol H, et al. Lenacapavir Oral Bridging (300 mg QW) Maintains Efficacy with a Similar Safety Profile When SC LEN Cannot Be Administered [Oral OAB0205] Presented at:12th International AIDS Society (IAS) Conference on HIV Science, 2023 23-26 July.
- Margot NA, Naik V, VanderVeen L, Anoshchenko O, Singh R, Dvory-Sobol H, Rhee MS, Callebaut C. Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir. J Infect Dis. 2022 Nov 28;226(11):1985-1991. doi: 10.1093/infdis/jiac364.
- Antinori A, Castelli F, Ronot-Bregigeon S, Yazdanpanah Y, Safran R, S. Berger DS, et al. Common Adverse Events in Clinical Studies of People Using Lenacapavir for HIV Treatment [P027]. Presented at: HIV Glasgow 2022, October 23-26
- Ogbuagu O, Segal-Maurer S, Ratanasuwan W, Trottier B,4 Brunetta J, Shirasaka T, et al. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People With Multi-Drug Resistant HIV: Week 52 Results [Oral 1585]. Presented at: IDWeek 2022, October 19-23
- Castagna A, J Blanco JL, Hung CC, Rassool M, Ramgopal MN, Sanchez W, et al. Week 52 Subgroup Efficacy Analyses of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People With Multidrug-Resistant HIV (CAPELLA Study) [P026]. Presented at: HIV Glasgow, 2022 October 23-26
- Kumar P, Gupta S, Segal-Maurer S, Ogbuagu O, McDonald C, Brinson C, et al. Injection-Site Reaction Experience in Clinical Studies of People Using Lenacapavir For HIV Treatment [Poster EPB184]. Presented at: AIDS, 2022 29 July-2 August
- Segal-Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, Siripassorn K, Ruane PJ, Berhe M, Wang H, Margot NA, Dvory-Sobol H, Hyland RH, Brainard DM, Rhee MS, Baeten JM, Molina JM; CAPELLA Study Investigators. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2022 May 12;386(19):1793-1803. doi: 10.1056/NEJMoa2115542.
- Margot N, Laurie VanderVeen L, Naik V, Chang S, Parvangada PC, Martin R, et al. Resistance Analysis of Long-Acting Lenacapavir in Highly Treatment-Experienced People with HIV After 26 Weeks of Treatment [Oral OS1/1]. Presented at: European AIDS Conference (EACS); 2021 October 27-30
- Stellbrink HJ, DeJesus E, Segal-Maurer S, Castagna A, Avihingsanon A, Blanco Arevalo JL, et al. Subgroups Efficacy Analyses of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People with HIV (CAPELLA study) [Abstract PE2/69]. Presented at: European AIDS Conference (EACS); 2021 October 27-30
- Segal-Maurer S, Castagna A, Berhe M, et al. Potent Antiviral Activity of Lenacapavir in Phase 2/3 in Heavily ART-Experienced PWH [Abstract 127]. Presented at: Conference on Retroviruses and Opportunistic Infections; 2021 March 6-10
- Ogbuagu O, Wiznia A, McGowan JP, Berger DS, Creticos CM, Hagins D, Hodge T, Osiyemi O, Sims J, Wheeler DA, Wang H, Margot NA, Dvory-Sobol H, Rhee MS, Segal-Maurer S, Molina JM. Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study. Open Forum Infect Dis. 2025 Dec 19;13(1):ofaf763. doi: 10.1093/ofid/ofaf763. eCollection 2026 Jan.
- Margot NA, Jogiraju V, Pennetzdorfer N, Naik V, VanderVeen LA, Ling J, Singh R, Dvory-Sobol H, Ogbuagu O, Segal-Maurer S, Molina JM, Rhee MS, Callebaut C. Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years. J Infect Dis. 2025 Jun 2;231(5):1239-1245. doi: 10.1093/infdis/jiaf050.
- Ogbuagu OE, Avihingsanon A, Segal-Maurer S, Wang H, Jogiraju VK, Singh R, Rhee MS, Dvory-Sobol H, Sklar PA, Molina JM. Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered. AIDS. 2025 May 1;39(6):639-648. doi: 10.1097/QAD.0000000000004142. Epub 2025 Feb 10.
- Ogbuagu O, Molina JM, Chetchotisakd P, Ramgopal MN, Sanchez W, Brunetta J, Castelli F, Crofoot GE, Hung CC, Ronot-Bregigeon S, Margot NA, Wang H, Dvory-Sobol H, Rhee MS, Segal-Maurer S. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial. Clin Infect Dis. 2025 Mar 17;80(3):566-574. doi: 10.1093/cid/ciae423.
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- GS-US-200-4625
- 2019-003814-16 (EudraCT nummer)
- 2019 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .